BTIG Research Increases Boston Scientific (NYSE:BSX) Price Target to $132.00

Boston Scientific (NYSE:BSX) had its target price hoisted by BTIG Research from $127.00 to $132.00 in a research report report published on Wednesday morning, Marketbeat.com reports. They currently have a buy rating on the medical equipment provider’s stock.

BSX has been the topic of several other reports. Wells Fargo & Company increased their price target on Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. Barclays raised their target price on Boston Scientific from $125.00 to $133.00 and gave the stock an “overweight” rating in a report on Thursday, July 24th. Canaccord Genuity Group boosted their price target on Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a report on Wednesday. UBS Group raised their price objective on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Thursday, July 24th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $121.00 target price on shares of Boston Scientific in a research note on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $120.79.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $97.30 on Wednesday. Boston Scientific has a twelve month low of $80.64 and a twelve month high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The company has a market cap of $144.17 billion, a PE ratio of 57.91, a price-to-earnings-growth ratio of 2.32 and a beta of 0.61. The company’s 50 day moving average is $102.93 and its 200 day moving average is $102.05.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business’s revenue for the quarter was up 22.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, sell-side analysts forecast that Boston Scientific will post 2.85 EPS for the current year.

Insider Activity at Boston Scientific

In related news, Director Yoshiaki Fujimori sold 2,901 shares of the business’s stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. The trade was a 58.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the company’s stock in a transaction on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director owned 18,479 shares of the company’s stock, valued at $1,959,328.37. This represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock worth $17,972,457 over the last 90 days. 0.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Boston Scientific

A number of large investors have recently added to or reduced their stakes in BSX. Brighton Jones LLC raised its position in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the period. Amplius Wealth Advisors LLC raised its stake in Boston Scientific by 5.5% in the 1st quarter. Amplius Wealth Advisors LLC now owns 2,381 shares of the medical equipment provider’s stock valued at $240,000 after purchasing an additional 124 shares during the last quarter. Veracity Capital LLC purchased a new position in Boston Scientific in the 1st quarter valued at $210,000. Leverty Financial Group LLC boosted its stake in Boston Scientific by 29.7% during the 1st quarter. Leverty Financial Group LLC now owns 3,977 shares of the medical equipment provider’s stock worth $401,000 after purchasing an additional 910 shares during the last quarter. Finally, Secure Asset Management LLC purchased a new stake in shares of Boston Scientific during the first quarter worth $418,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.